Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of
radiation directly to the tumor may kill more tumor cells and cause less damage to normal
tissue. Giving these treatments before surgery may make the tumor smaller and reduce the
amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying the side effects of giving cetuximab together with
cisplatin and docetaxel before radiation therapy and cetuximab followed by surgery and to see
how well it works in treating patients with stage IIIB non-small cell lung cancer that can be
removed by surgery.